For how we live.
In 947 Chinese children followed for ten years, those with insulin resistance despite normal blood sugar had a 4.3-fold higher risk of later dysglycaemia, and six amino acids helped predict who would develop it.
In 7,186 Korean adults followed up to 20 years, people flagged by fasting glucose, glucose tolerance and HbA1c all at once had a 15.3-fold higher risk of type 2 diabetes than normal controls.
An Israeli records study of 181,000 adults found people now diagnosed are older and sicker, but start with better glucose and cholesterol, and far more leave the clinic on SGLT2 or GLP-1 drugs.
An observational study of 8,127 UK women on GLP-1 drugs, almost all tirzepatide, reported 16.1 kg average loss at six months and 91.4% retention. There was no control arm.
In the phase 3 SYNCHRONIZE-2 trial, the glucagon/GLP-1 dual agonist beat placebo on weight over 76 weeks. The effect was solid but smaller than the class leaders manage, and the maker funded it.
Two phase 3 trials put the oral drug safiglipron ahead of placebo and non-inferior to dapagliflozin on HbA1c. Both ran only in China, were maker-funded, and showed dose-dependent gut side effects.
ACHIEVE-4 found the non-peptide GLP-1 pill non-inferior to insulin glargine for major cardiac events over two years, with less severe hypoglycaemia but far more gastrointestinal upset. Lilly funded it.
A small crossover trial found 5 mg of melatonin worsened glucose handling and cut early insulin secretion in people carrying the MTNR1B risk variant, but not in non-carriers.
Both raise blood sugar, but for opposite reasons. Type 1 is an autoimmune loss of insulin; type 2 is the body resisting the insulin it makes. Type 2 accounts for 90 to 95 percent of cases.
A short walk after eating blunts the post-meal blood-sugar spike. Trials in people with type 2 diabetes and in healthy adults agree, and light walking beats standing, which beats sitting still.
A limb that has "gone to sleep" is brief pressure on a nerve and clears in minutes. Tingling that is persistent or spreading can mean carpal tunnel, diabetes or low B12; sudden one-sided numbness is an emergency.
Insulin resistance usually causes no symptoms you can feel, which is why it is found through blood tests rather than how you seem. The visible clues are subtle — and it rarely travels alone.
Trials can show cinnamon nudging fasting glucose down, but the effect is inconsistent, leaves long-term control (HbA1c) untouched, and cheap cassia cinnamon carries a coumarin safety flag.
A banana is mostly sugar and starch, but it comes with fibre and potassium, and large cohort studies link whole fruit — bananas included — to slightly lower type 2 diabetes risk, not higher.
No long-term trial has tested an all-meat diet. The best direct data is a self-reported survey where people felt better but ran markedly high LDL cholesterol — the signal that should give pause.
Obesity and metabolic syndrome push men's testosterone down. One large trial shows testosterone can cut new diabetes modestly, but the effect is smaller than weight loss and comes with safety trade-offs.
The honest answer is that early type 2 diabetes usually has no signs you can feel. The classic symptoms arrive late, and damage can be under way years before the diagnosis is made.
Yes — the hormones released under stress push glucose up, which is why steroids and severe illness cause hyperglycaemia. Whether everyday stress raises long-term diabetes risk is a smaller, murkier effect.
US preventive guidelines back a blood-sugar test for adults 35 to 70 who carry extra weight; the main diabetes body would test every adult from 35. The gap is about how wide a net catches enough real disease.
Federal statistics put 18.3 million households short of food last year. A 57,404-person cohort links lower food security to higher premature mortality and years of lost life expectancy.
A small 1990s trial hinted selenium supplements cut cancer, launching a supplement boom. The much larger SELECT trial found no benefit — and signals of harm, including more type 2 diabetes.
A large treadmill cohort found the least-fit adults had about five times the death rate of the fittest — a bigger risk than coronary disease, smoking or diabetes. But it measures a state, not a lever.
A widely cited cohort found people with diabetes on metformin outlived matched non-diabetic controls. It fuelled the TAME anti-ageing trial — but the human signal is observational, and TAME is not running.
A 2025 meta-analysis of 10 trials found small, short-term reductions in weight and BMI — but the studies were heterogeneous, and the viral single trial that fuelled the hype is one small study, not a settled result.
The popular claim is that a shot before meals fires up digestion. The controlled measurement shows vinegar slows the stomach down — helpful for blood sugar, unhelpful if you already digest slowly.
Six months of dietitian sessions aimed at a high-fibre diet nudged diet quality but left estimated 10-year cardiovascular risk, HbA1c, cholesterol and blood pressure essentially unchanged versus standard care.
Honey and table sugar are both free sugars with almost identical calories. Trials hint at small metabolic differences in honey's favour, but the certainty is low and honey is still added sugar to be limited.
These soft flaps are harmless. Their real interest is metabolic — one study tied them to diabetes with an odds ratio of 1.89 — but a 2026 cohort found no link to prediabetes. Removal is cosmetic, not a home job.
Prediabetes is a high-risk state, not a diagnosis of diabetes. In the trial that defined the field, lifestyle change cut progression by 58 percent — and returning to normal glucose carried a benefit of its own.
Sugars bond to proteins to form advanced glycation end products that accumulate with age and stiffen tissue. Low-AGE diets nudge metabolic markers, but no trial shows they slow ageing.
Whole fruit and fruit juice behave oppositely for type 2 diabetes risk, and a trial that told newly diagnosed patients to eat less fruit found no benefit at all.
In a tightly controlled feeding trial, swapping high-GI for low-GI carbohydrate inside a healthy diet did not improve insulin sensitivity, cholesterol or blood pressure. The wider evidence rates the GI case as weak.
Higher whole-grain intake is consistently linked to lower rates of heart disease, cancer and early death, with benefit rising up to about seven servings a day. Refined grains show no such signal.
Cohorts link both to modestly higher rates of heart disease and early death, on low-certainty evidence. A 2019 guideline then told people to keep eating them — and split the field over how to weigh nutrition science.
Large randomised trials mostly find no cardiovascular benefit from ordinary fish-oil capsules. One high-dose prescription drug is the striking exception, and the case for brain protection is weak.
People who eat nuts have lower rates of heart disease and early death in large cohorts, and a Mediterranean diet with nuts cut cardiovascular events in one trial. Most of the evidence is observational.
Whole fruit is linked to lower type 2 diabetes risk, sugary drinks to clearly higher risk, and fruit juice sits closer to the drinks than to the fruit it comes from.
Across nearly 1.1 million people, each extra daily cup tracks with lower diabetes risk in a clear dose-response. It is consistent and large — and still only observational.
Saving starch for the end of a meal reliably blunts the glucose rise afterwards in small trials — but the evidence is short-term, low-certainty, and silent on whether it changes long-term control.
In QWINT-1, fixed-dose weekly efsitora cut HbA1c about as much as daily glargine in 795 insulin-naive adults — with a lower rate of significant hypoglycaemia and a quarter of the dose changes.
A twins trial found a vegan diet lowered LDL cholesterol, insulin and weight in eight weeks. The same pattern comes with real gaps — vitamin B12 must be supplemented, and iron stores tend to run lower.
Marketed as a natural weight-loss drug, berberine rests on small, mostly low-quality trials showing modest effects on blood sugar and cholesterol — with no weight-loss evidence to match the hype.
Head-to-head randomised trials find low-carbohydrate and low-fat diets produce similar weight loss over a year or two. The differences that survive are in blood lipids and glycemic control, not the scale.
Zenagamtide was tested as a weekly injection and a daily pill in type 2 diabetes. Both cut HbA1c against placebo at 36 weeks, and the oral version's side effects rose steeply with dose.
Three randomised trials found routine finger-prick testing produced no clinically meaningful change in long-term blood sugar for people whose type 2 diabetes is managed without insulin.
Substantial, sustained weight loss can return blood sugar to the normal range without drugs in some people diagnosed recently. It is real, it is not a cure, and it fades as the weight comes back.
It extends life in yeast, worms and flies, and in mice on a high-fat diet. In people it fails to reliably switch on the enzyme it targets, and higher intake tracks no drop in death, cancer or heart disease.
EECOH-1 randomised 211 adults and found the weekly GLP-1 cut HbA1c up to 1.56 points more than placebo over 24 weeks — competitive numbers from a short, single-country, company-run trial.
A 411,000-patient claims study found adults on GLP-1 drugs who started oxycodone had more severe constipation and bowel obstruction at 30 days than those starting hydrocodone or tramadol.
In 69 people across normal weight, overweight and type 2 diabetes, a stevia drink behaved like water — no shift in glucose, insulin, gut hormones, appetite or how much they ate next.
A Lancet review triangulates the evidence linking adiposity to multisystem disease and finds robust trial support in a short list — while an expert panel argues the drugs must be lifelong.
Matched against DPP-4 inhibitors, GLP-1 users had slightly more diabetic retinopathy and more retinopathy procedures. Vision impairment and blindness did not differ — and the coding for those is poor.
A Lancet series covering 135 million person-years found the largest risk reductions in that range. Trials of isolated fibre supplements produce much smaller effects on much narrower outcomes.
A supplement approved on 26 August adds SURPASS-CVOT to the prescribing information and rewrites the eye warning so it is addressed to patients with a history of retinopathy rather than to patients with diabetes.
A 1.5-million-person records study reports lower mortality with GLP-1 drugs than with SGLT2 inhibitors, and the largest absolute gains in people with serious mental illness. The design cannot prove it.
A sibling-controlled cohort of 1.1 million men, a genetic analysis of 712 traits and a UK Biobank study of fitness change converge — and they agree on where the exception is.
Across 89,573 accelerometer-monitored adults and 678 conditions, no disease showed a significant difference between activity concentrated in one or two days and activity spread through the week.
Two WHO bodies reported on the same day in July 2023 and reached findings that sound contradictory. Both were right, because they were answering different questions.
Two 2026 meta-analyses of type 2 diabetes apps found HbA1c reductions of 0.39 and 0.58 points versus usual care — modest, clinically meaningful, and consistent, though the trials vary widely in quality.
A 2025 meta-analysis of 57 studies found the mortality curve bending at about 7,000 steps a day. The 10,000 figure traces to the trade name of a Japanese step counter sold in 1965.
In February, FDA said it intended to act against compounded GLP-1 supply without saying how. The answer arrived in May: exclude semaglutide, tirzepatide and liraglutide from the list.
Four separate trial emulations, each with a different comparator, all pointed the same direction. The strongest effect appeared among people being treated for alcohol use disorder.
Tirzepatide and semaglutide showed comparable psychiatric risk profiles against each other over two years. Against earlier GLP-1 drugs, semaglutide came out ahead on all three measures.
Lilly's oral GLP-1 pill actually lowered liver enzymes on average, and its rate of serious liver-injury criteria matched placebo exactly — six cases in each group, none attributable to the drug.
Pooling 2,906 participants, researchers ranked how antidiabetic drugs affect fat versus lean body mass. Exercise blunted liraglutide's muscle loss; metformin, insulin, and DPP4 inhibitors barely moved either measure.
In TRANSCEND-T2D-1, the triple-hormone agonist cut HbA1c up to 1.12 points beyond placebo over 40 weeks and trimmed bodyweight 15.3% at the top dose in early type 2 diabetes.
After 12 months, HbA1c was 6.5% among people managed by community health workers versus 7.1% among those referred to clinics. With 103 participants analysed, the confidence interval crosses zero.
The ESC Atlas reports 68 million disability-adjusted life years and more than three million cardiovascular deaths a year, with middle-income countries carrying roughly double the mortality of high-income ones.
The LiverScreen project ran transient elastography across nine countries, then sent everyone who screened positive to a hepatologist. The gap between the two numbers is the interesting part.
Awiqli's approval for adults with type 2 diabetes rests on four trials comparing it with daily basal insulin. A pediatric dosing study is still due by June.
OCULUS was halted at interim analysis: continuing a GLP-1 or GIP agonist before endoscopy left 25.0% of patients with clinically significant retained stomach contents, versus 3.1% who held one dose.
A survey-based analysis of the European Health Interview Survey puts a price on Europe's obesity-related hospital use, and finds the strongest single association is not with obesity at all.
Pooling 94 cohort studies, grip strength tracked with later dementia, depression and disability. The authors rate their own confidence in the numbers as limited to moderate.
Compared with a diabetes drug from another class, GLP-1 agonists were followed by fewer new diagnoses of alcohol, opioid, nicotine and other substance use disorders.
ACHIEVE-3 randomised 1,698 people to orforglipron or oral semaglutide for 52 weeks. Orforglipron cut HbA1c more at every dose comparison — and produced more side effects and more dropouts.
The agency announced an intent to restrict GLP-1 active ingredients destined for non-approved compounded drugs, and warned that seizure and injunction are on the table without further notice.
In a 618-person randomized trial, 27.8% of the intervention group met the sustained-remission endpoint at 24 months against 21.2% of comparators. The confidence interval nearly touches no effect.
Large taxed beverage sales fell 24 to 31 percent under the tax. In the period after repeal they remained 13 to 24 percent below pre-tax levels — and prices stayed elevated too.
A December survey found getting stronger is the leading 2026 health goal. The best meta-analysis of muscle-strengthening and mortality finds a benefit that plateaus at around 30 to 60 minutes a week.
Matched against a comparator diabetes drug, incretin agonists were associated with an 8% lower rate of CPAP procedures — alongside a 32% lower mortality that should make readers cautious.
A UK Biobank analysis of 96,365 people found a dose-response relationship between lifetime night-shift exposure and cardiovascular-kidney-metabolic disease — amplified in those who also slept short.
The headline finding is noninferiority. The more useful finding is what the shared denominator was — and how wide a gap the trial was designed to tolerate.
The ADA's 2026 Standards of Care add guidance on individualising obesity-drug dosing, name two eating patterns for type 2 diabetes prevention, and recommend continuous glucose monitoring from diagnosis.
Two November burden analyses put diabetes diagnosed before 40 on an upward path to 2050. In the Americas, Central Latin America carried the highest rates and men carried more of the burden than women.
In ATTAIN-2, the highest dose of the oral GLP-1 pill cut body weight 9.6% over 72 weeks in adults with type 2 diabetes, against 11.2% in the earlier trial of adults without diabetes.
The 27 recommendations cover monitoring, diet and medication for type 1, type 2 and gestational diabetes. WHO had guidance on diabetes and guidance on pregnancy, but never on the two together.
Head-to-head in US insurance data, the two drugs showed comparable cardiovascular outcomes and comparable rates of severe gastrointestinal events in type 2 diabetes. Neither study was a trial.
VESALIUS-CV randomised 12,257 patients with atherosclerosis or diabetes but no prior MI or stroke. Evolocumab reduced the three-point event rate from 8.0% to 6.2% over a median 4.6 years.
SURPASS-CN-INS randomised 257 adults at 26 Chinese hospitals. The 10 mg and 15 mg doses performed almost identically against placebo, and diarrhoea affected roughly a third of those on the higher doses.
Pooling individual data from 23,340 people in four trials, empagliflozin cut kidney failure by 34% and slowed eGFR decline by 64% — regardless of how big an initial creatinine rise was expected.
A pooled analysis of 72,776 Korean adults found an 11% higher type 2 diabetes risk in the top intake quartile. An updated meta-analysis of 17 cohorts put the dose-response at 10% per 10% of intake.
Two phase 3b trials tested semaglutide 7.2 mg against the approved 2.4 mg dose. The extra weight loss was real but modest, and gastrointestinal side-effects and dysaesthesia rose alongside it.
A Spanish trial in 4,746 adults compared an energy-reduced Mediterranean diet plus exercise against the same diet eaten freely. Over six years the absolute gap was 12.0% versus 9.5%.
A meta-analysis of pedometer, tracker and smartwatch interventions lasting 12 to 48 weeks found no significant change in systolic or diastolic pressure — nor in weight, glucose or HbA1c.
Dapagliflozin beat placebo on liver histology over 48 weeks in six Chinese hospitals. Weeks later, European regulators recommended the first purpose-built drug for the same disease.